Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer's Disease

Area of Science:

• Neuroscience and Pharmacology
• Medicinal Chemistry

Background:

• Alzheimer's disease (AD) presents a growing challenge with current therapies offering only temporary relief.
• Existing treatments primarily rely on acetylcholinesterase inhibition.
• AD is a multifactorial disease requiring diverse therapeutic strategies beyond simple enzyme inhibition.

Purpose of the Study:

• To explore the potential of cinnamic acid derivatives as novel therapeutic leads for Alzheimer's disease.
• To evaluate the efficacy of cinnamic acid derivatives in inhibiting amyloid-beta (Aβ) accumulation and providing neuroprotection.
• To investigate structure-activity relationships of cinnamate compounds, focusing on substitutions and their impact on efficacy.

Main Methods:

• Review and analysis of existing literature on cinnamate derivatives and their application in AD.
• Evaluation of cinnamate derivatives as butyrylcholinesterase (BuChE) inhibitors and multi-target ligands (MTDLs).
• Assessment of compounds targeting oxidative stress and inflammation in the context of AD.

Main Results:

• Cinnamate derivatives demonstrate neuroprotective properties and potential for inhibiting Aβ accumulation.
• Compounds with methoxy substitutions at the para-position of cinnamic acid show increased efficacy.
• Electron-withdrawing groups generally enhance the effectiveness of cinnamate derivatives.

Conclusions:

• Cinnamic acid serves as a versatile scaffold for developing novel Alzheimer's disease therapeutics.
• Optimized cinnamate derivatives offer a promising alternative or adjunct to current AD treatments.
• Further investigation into molecular volume effects is warranted for refining cinnamate-based drug design.